-
Over 300,000 people study: the more these foods are eaten, the higher the risk of breast cancer may be
Time of Update: 2021-06-17
The study found that regular consumption of pro-inflammatory foods is associated with an increased risk of breast cancer; and the more consumed, the higher the risk of breast cancer .
A pro-inflammatory diet rich in red meat, processed meat, sugar, and saturated fat can increase inflammation and increase the risk of breast cancer .
-
Sofantinib SANET-p research subgroup analysis is listed on ASCO, continues to write brilliant
Time of Update: 2021-06-17
In 2021, the American Society of Clinical Oncology (ASCO), a SANET-p study of Sofatinib in the treatment of pancreatic neuroendocrine tumors (p-NET) released the latest subgroup data, the results showed that regardless of Ki-67 expression level or baseline CgA Regardless of the level, Sofatinib has significant benefits in patients with advanced, progressive, and moderately well-differentiated p-NET .
-
2021 Efficacy and safety of ASCO Zebutinib vs. Rituximab-based immunochemotherapy in Waldenstrom's macroglobulinemia (WM): an indirect comparison of matching adjustments
Time of Update: 2021-06-17
In February 2021, the US FDA based on 3 The phase clinical study ASPEN accepted zebutinib for patients with Waldenstrom's macroglobulinemia who had previously received a therapy, or as the first-line treatment for WM patients with immunochemotherapy .
Compared with receiving DRC, Zebutinib treatment significantly prolonged PFS (pre-match hazard ratio [HR]: 0.
-
ASCO: Entering the harvest period ASCO 2021
Time of Update: 2021-06-17
On June 8, Yasheng presented two oral reports related to cell apoptosis products at the ASCO conference: about APG-2575 in patients with relapsed and refractory chronic lymphocytic leukemia (R/R CLL) and other hematological tumors Safety and efficacy, as well as the preliminary results of a phase II clinical study of APG-115 combined with pembrolizumab for the treatment of resistant unresectable/metastatic melanoma or advanced solid tumor patients with PD-1 inhibitors .
-
15 years of research on more than 300,000 women, the more such foods are eaten, the higher the risk of breast cancer
Time of Update: 2021-06-17
The research team said that after excluding factors including weight, drinking habits and exercise, the link between inflammatory diet and breast cancer risk still exists .
-
ASCO 2021 synchronizes 6 top medical journals, Ma Jun team’s nasopharyngeal cancer research published this morning
Time of Update: 2021-06-17
The significance of this study is that the authors confirmed for the first time in a phase 3 randomized controlled trial that capecitabine rhythm chemotherapy adjuvant treatment of high-risk locally advanced nasopharyngeal carcinoma can improve the survival rate of patients .
-
The Phase II clinical data of KN046 combined with chemotherapy in the first-line treatment of esophageal squamous cell carcinoma will be announced on ASCO 2021
Time of Update: 2021-06-17
June 7, 2021, Suzhou, China-Corning Jereh Biopharmaceuticals (stock code: 9966. HK) announced that it will announce PD-L1/CTLA in the form of a poster at the 2021 American Society of Clinical Oncolog
-
ASCO 2021: Fate's iPSC-derived NK cell clinical data is active
Time of Update: 2021-06-17
Recent popular reports from Yimaike ★ Invitation to the event 2021 Oncolytic Virus Drug Development Forum is about to open in Shanghai ★ The financing has been hundreds of millions in half a year, an
-
3-year OS rate 61% KEYNOTE-177 OS analysis results "shown" ASCO
Time of Update: 2021-06-17
S. Food and Drug Administration (FDA) approved the PD-1 immune checkpoint inhibitor Pabolizol based on the positive results of the progression-free survival (PFS) in the study Monoclonal antibody (K drug) is the first-line treatment for unresectable or metastatic colorectal cancer (mCRC) of MSI-H/dMMR .
-
The first-line, neoadjuvant treatment of advanced gastric cancer is progressing rapidly, and innovative therapies are expected to change clinical practice. 2021ASCO Gastric Cancer Special
Time of Update: 2021-06-17
*Only for medical professionals to read and refer to Fudan Cancer Experts Interpretation of 2021 ASCO New Progress in Gastric Cancer Diagnosis and Treatment! The 2021 American Society of Clinical Onc
-
Ji Chushu: Fatigue is another peak in palliative care. Tumor symptom management column ③
Time of Update: 2021-06-17
In the past, long-term surviving patients have new accompanying symptoms, of which the higher incidence is cancer-related fatigue, which is not less than 40% in clinical practice .
-
2021 ASCO OUTBACK study: locally advanced cervical cancer adjuvant chemotherapy does not benefit
Time of Update: 2021-06-17
The results show that adding adjuvant chemotherapy to standard radiotherapy and chemotherapy cannot improve the survival outcome of patients with locally advanced cervical cancer, and the incidence of adverse events is higher .
-
STTT Shandong University Lou Hongxiang/Yuan Huiqing discovers potential therapeutic targets for multidrug resistance
Time of Update: 2021-06-17
In this study, a new mechanism was revealed by which TFE3/lysosomes activate the response to therapeutic agents, such as docetaxel (Doc), by promoting the dissolution of multidrug resistance-related protein 2 (MRP2).
-
ADC can improve the remission rate of patients with advanced urothelial cancer
Time of Update: 2021-06-17
Commentary author: Robert Dreicer, MD, MS, MACP, FASCO antibody-drug conjugate sacituzumab govitecan makes platinum Patients with disease progression after similar chemotherapy and immunotherapy achieved an objective remission rate of 27% .
-
More than half of ASCO patients achieved complete remission, and early clinical results of "ready-to-use" NK cell therapy were positive
Time of Update: 2021-06-17
▎The content team editor of WuXi AppTec recently, Fate Therapeutics announced at the 2021 American Society of Clinical Oncology (ASCO) annual meeting that it announced its research on natural killer cell (NK cell) therapy FT516, combined with rituximab to treat relapse/refractory Data from an active phase 1 clinical trial in patients with sexual B-cell lymphoma .
-
The first domestic self-developed ADC was approved for the treatment of gastric cancer, medical doctor Mai Meng broke the news
Time of Update: 2021-06-17
6%Yimai Meng broke the news, click on the picture, and register now June 9, 2021 / Yimaike News eMedClub News/-June 9th, China National Medical Products Administration (NMPA) announced that Rongchang Biological application Vidicitor for injection (trade name: Aidixi) has passed the priority review and approval procedure with conditional approval for listing .
-
The era of chemotherapy alone for "Chinese characteristic tumors" may end
Time of Update: 2021-06-17
The team of Professor Zhang Li from Sun Yat-sen University Cancer Center has conducted a series of studies in order to explore more effective treatment options and improve the survival status of patients with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) .
-
ASCO first-line treatment of specific non-small cell lung cancer, Novartis announces overall survival data for MET inhibitors
Time of Update: 2021-06-17
▎The content team editor of WuXi AppTec recently, at the American Society of Clinical Oncology (ASCO) in 2021, Novartis announced the oral high-selective small molecule MET inhibitor Tabrecta (capmatinib) for the treatment of metastatic non-small cell lung cancer (NSCLC) The latest Phase 2 clinical trial data for adult patients .
-
Esophageal Squamous Cell Carcinoma (ESCC) Immunotherapy!
Time of Update: 2021-06-17
Compared with chemotherapy, Opdivo+chemotherapy, Opdivo+Yervoy in the patient population with tumor cell PD-L1 expression ≥1%, in all random patient populations, make OS have a statistically significant and clinically significant improvement in tumors The specific data are as follows: (1) Among patients with tumors expressing PD-L1, the median OS of the 1Opdivo+ chemotherapy group was 15.
-
Multiple clinical research data of dual antibodies KN046 and KN026 will be unveiled in ASCO 2021, covering multiple tumor types such as lung cancer and pancreatic cancer
Time of Update: 2021-06-17
*Only for medical professionals to read and reference. Recently, 3 clinical research data of KN046 (PD-L1/CTLA-4 bispecific antibody) will be presented in the ASCO 2021 annual meeting in the form of
